Asia Pacific Oncology Based Molecular Diagnostics Market Share Analysis Report, 2024-2033
The Asia Pacific oncology based molecular diagnostics market size was estimated at USD 645.90 million in 2023 and is projected to hit around USD 2,628.97 million by 2033, growing at a CAGR of 15.07% during the forecast period from 2024 to 2033.
Key Takeaways:
Asia Pacific Oncology Based Molecular Diagnostics Market Growth
The rising prevalence of various types of cancer, such as breast, prostate, and colon, along with the increase in geriatric population, advancement in technology, rising necessity of point-of-care testing (POCT), and growth in biomarker identification systems, are predicted to be the major drivers for the market. In addition, the increase in demand for precise and quick diagnosis, coupled with advancements in Next Generation Sequencing (NSG) techniques, and increased awareness of personalized medications are also major market boosters.
In the year 2020, Asia accounted for 45% of the worldwide total of 2.3 million breast cancer cases and more than 50% of all cervical cancer cases. Furthermore, every country in the region is experiencing an increase in breast cancer deaths. It’s projected that by 2025, countries like Indonesia and the Philippines will see a nearly 20% increase in breast cancer mortality compared to 2020. The National Cancer Institute reports approximately 439.2 new cases and 163.5 deaths per 100,000 people annually. Thus, molecular diagnostics provide insights into the biology of a patient’s tumor and are crucial in cancer management. Furthermore, the demand for home healthcare and other medical establishments is increasing due to an aging population and government initiatives to reduce hospital stays, which is expected to boost the demand for point-of-care diagnostics. Significant growth opportunities exist in over-the-counter and rapid diagnostic product segments, particularly in Asian countries with rapid economic growth.
Minimally invasive diagnostic procedures are becoming more popular as they offer quicker recovery times compared to invasive procedures. These procedures, including needle-based blood tests, biomarker tests, and biopsies, allow for the screening of tumors before complex surgical procedures. They aid in accurate cancer diagnosis, help physicians determine the best treatment plan, and minimize patient discomfort. Technological advancements leading to accurate results, portability, and cost-effectiveness are expected to drive this market. For tumor diagnosis, companies like Sigma Aldrich Corporation and Qiagen are developing new molecular diagnostic techniques, such as Loop-Mediated Isothermal Amplification (LAMP) and Transcription-Mediated Amplification (TMA). For instance, Sigma Aldrich Corporation is engaged in advancing the principles and applications of diagnostic molecular microbiology. Their focus lies on state-of-the-art methods such as nucleic acid probes and in vitro amplification, which are utilized for pathogen identification.
Asia Pacific Oncology Based Molecular Diagnostics Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 743.24 million |
| Market Size by 2033 | USD 2,628.97 million |
| Growth Rate From 2024 to 2033 | CAGR of 15.07% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Type, technology, product, country |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Abbott Laboratories; Agilent Technologies Inc; bioMerieuz SA; Danaher; F. Hoffmann-La Roche Ltd.; Illumina Inc; Novartis AG; Qiagen NV; Siemens Healthineers AG; TBG Diagnostics Limited; Thermo Fisher Scientific Inc; Sysmex |
China Oncology Based Molecular Diagnostics Market Trends
The oncology based molecular diagnostics market in China is growing lucratively over the forecast period. The universal healthcare system is the primary form of Chinese healthcare, which consists of basic medical insurance, serious illness aid, urban & rural medical assistance, and critical illness insurance. This is one of the initiatives undertaken by the government to increase access to healthcare. Rising government initiatives and huge unmet clinical needs are some of the factors expected to drive the market over the forecast period.
India Oncology Based Molecular Diagnostics Market Trends
The oncology based molecular diagnostics market in China is expanding significantly over the coming years. According to data published by WHO, it has been estimated that incidence of cancer in India is very high with an alarming mortality rate, i.e., about 806,000 existing cases and mortality of about 0.3 million deaths per year due to lack of availability of diagnosis and treatment options. In addition, there are internal as well as external factors that can be attributed to the high incidence rate—internal factors like (genetic, mutations, hormonal, poor immune conditions, etc.) and external factors such as (unhealthy food habits, industrialization, overgrowth of population, social, and more). These factors are key drivers of the market and contribute to the improving economic status of this nation. This factor coupled with high demand for better diagnosis and preventive medicine is expected to boost the oncology-based molecular diagnostics market growth.
Segments Insights:
Type Insights
The main types of cancer studied under this segment include breast cancer, prostate cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer, blood cancer, and kidney cancer, among others. Of these, breast cancer dominated the overall market in 2023 in terms of revenue share due to large test volumes and an extensive portfolio of commercialized products. For instance, a consensus was reached at the ESMO Asia Congress 2023 on practical gaps in genetic counselling and testing, risk assessment, and management of germline BRCA mutations (gBRCAm)-associated breast cancer (BC) in the Asia-Pacific region.
On the other hand, liver cancer and prostate cancer diagnostics markets are also estimated to witness significant growth, in addition to colorectal cancer, due to rising prevalence and increasing awareness levels among consumers. Broad avenues mark oncology-based molecular diagnostics for the development of diagnostic technology at molecular levels in personalized medicine for medication and new drug discovery.
Technology Insights
The polymerase chain reaction (PCR) technology segment held the highest revenue share of 31.15% in 2023. This can be attributed to its growing utilization in research labs and the increased need for enhanced diagnostics. The industry is segmented based on technology into seven major types, which include polymerase chain reaction (PCR), In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Chips and microarrays, Mass Spectrometry, Sequencing, and Transcription Mediated Amplification.
The sequencing segment is anticipated to witness a significant growth rate of YY.Y% during the forecast period. The growth in demand for sequencing technology is augmented by an increase in research and development expenditure and the widespread use of sequencing technologies in clinical diagnosis, which is anticipated to provide a favorable environment for market expansion during the forecast period, due to its benefits such as quick turnaround times and speedier processing.
Product Insights
The reagents segment held the highest share of 58.59% of the overall revenue in 2023. This can be attributed to the high-volume usage of reagents for conducting tests and diagnostics in cancer research. The expansion in the field of molecular biology technology, progress in biotechnology advancements, rising demand for synthetic biology, and increasing investment in research and development by biotechnology companies are the main factors fueling the rapid growth of this industry segment.
The reagents segment is also anticipated to expand at a significant CAGR over the forecast period. The CE-IVD marked PD-L1 IHC 22C3 pharmDx assay from Agilent Technologies, Inc. was made available for esophageal cancer patients in August 2021. Using a cumulative positive score, this assay was employed to help identify individuals with esophageal cancer who would benefit from KEYTRUDA therapies.
Country Insights
Japan oncology based molecular diagnostics market accounted for the largest revenue share of 40.59% in 2023. High diagnosis rate and management of the disease is one of the major factors responsible for market growth in Japan. Japan’s population is 127 million and the proportion of the geriatric population is increasing rapidly, wherein the life expectancy rate is above 80 years and the per capita income is high. According to Japan’s Ministry of Health, Labor and Welfare, cancer is the major cause of death in Japan, contributing to around 30% of the total deaths. Aging has become a substantial risk factor for numerous diseases including cancer. The process of becoming older is a complex situation influenced by the interaction of several environmental and genetic factors. These factors are accelerating the growth in this region. Key market drivers in this region are increasing prevalence of cancer, growing awareness about genetic testing, and rising geriatric population.
Recent Developments
Key Asia Pacific Oncology Based Molecular Diagnostics Company Insights
The development of new products by key players has also resulted in the expansion of their existing product portfolio. Market players are constantly striving to innovate and improve their products. This involves investing in research & development to create products that are more efficient, effective, or cater to a wider range of customer needs. The launch of these new and improved products enhances their companies and attracts more customers. In addition to product innovation, market players are also engaging in strategic mergers and acquisitions. This strategy allows them to expand their market presence by gaining access to new markets, customer bases, and technologies that were previously inaccessible. This can also lead to cost efficiencies through economies of scale and scope, further enhancing their market position.n
Key Asia Pacific Oncology Based Molecular Diagnostics Companies:
The following are the leading companies in the Asia Pacific oncology based molecular diagnostics market. These companies collectively hold the largest market share and dictate industry trends. Financials, strategy maps & products of these Asia Pacific oncology based molecular diagnostics companies are analyzed to map the supply network.
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Asia Pacific Oncology Based Molecular Diagnostics market.
By Type
By Technology
By Product
By Country
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Technology
1.2.3. Product
1.2.4. Country scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. nova one advisor internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Asia Pacific
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Technology outlook
2.2.3. Product outlook
2.2.4. Country outlook
2.3. Competitive Insights
Chapter 3. Asia Pacific Oncology Based Molecular Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Asia Pacific Oncology Based Molecular Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Asia Pacific Oncology Based Molecular Diagnostics Market: Type Estimates & Trend Analysis
4.1. Asia Pacific Oncology Based Molecular Diagnostics Market: Type Dashboard
4.2. Asia Pacific Oncology Based Molecular Diagnostics Market: Type Movement Analysis
4.3. Asia Pacific Oncology Based Molecular Diagnostics Market Estimates and Forecasts, By Type, Revenue (USD Million)
4.4. Breast Cancer
4.4.1. Market estimates and forecasts, 2021 - 2032
4.5. Prostate Cancer
4.5.1. Market estimates and forecasts, 2021 - 2032
4.6. Colorectal Cancer
4.6.1. Market estimates and forecasts, 2021 - 2032
4.7. Cervical Cancer
4.7.1. Market estimates and forecasts, 2021 - 2032
4.8. Liver Cancer
4.8.1. Market estimates and forecasts, 2021 - 2032
4.9. Lung Cancer
4.9.1. Market estimates and forecasts, 2021 - 2032
4.10. Blood Cancer
4.10.1. Market estimates and forecasts, 2021 - 2032
4.11. Kidney Cancer
4.11.1. Market estimates and forecasts, 2021 - 2032
4.12. Other Cancer
4.12.1. Market estimates and forecasts, 2021 - 2032
Chapter 5. Asia Pacific Oncology Based Molecular Diagnostics Market: Technology Estimates & Trend Analysis
5.1. Asia Pacific Oncology Based Molecular Diagnostics Market: Technology Dashboard
5.2. Asia Pacific Oncology Based Molecular Diagnostics Market: Technology Movement Analysis
5.3. Asia Pacific Oncology Based Molecular Diagnostics Market Estimates and Forecasts, By Technology, Revenue (USD Million)
5.4. PCR
5.4.1. Market estimates and forecasts, 2021 - 2032
5.5. INAAT
5.5.1. Market estimates and forecasts, 2021 - 2032
5.6. Mass spectrometry
5.6.1. Market estimates and forecasts, 2021 - 2032
5.7. Sequencing
5.7.1. Market estimates and forecasts, 2021 - 2032
5.8. TMA
5.8.1. Market estimates and forecasts, 2021 - 2032
5.9. others
5.9.1. Market estimates and forecasts, 2021 - 2032
Chapter 6. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Estimates & Trend Analysis
6.1. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Dashboard
6.2. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Movement Analysis
6.3. Asia Pacific Oncology Based Molecular Diagnostics Market Estimates and Forecasts, By Product, Revenue (USD Million)
6.4. Instruments
6.4.1. Market estimates and forecasts, 2021 - 2032
6.5. Reagents
6.5.1. Market estimates and forecasts, 2021 - 2032
6.6. Others
6.6.1. Market estimates and forecasts, 2021 - 2032
Chapter 7. Asia Pacific Oncology Based Molecular Diagnostics Market: Country Estimates & Trend Analysis
7.1. Country Market Share Analysis, 2023 & 2030
7.2. Country Market Dashboard
7.3. Country Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts, 2021 - 2032
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts, 2021 - 2032
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts, 2021 - 2032
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts, 2021 - 2032
7.5.5. New Zealand
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. New Zealand market estimates and forecasts, 2021 - 2032
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.4. Company Profiles
8.4.1. Abbott Laboratories
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Agilent Technologies Inc
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. bioMerieux SA
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Danaher
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. F. Hoffmann-La Roche AG
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Illumina Inc
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Novartis AG
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Qiagen NV
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Siemens Healthineers AG
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. TBG Diagnostics Limited
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. Thermo Fisher Scientific Inc
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives
8.4.12. Sysmex
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product benchmarking
8.4.12.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers